Research Labs

Optimizing the use of Single high Dose Radiation Therapy (SDRT) in pre-clinical studies to activate innate immune signaling pathways, potentially leading to adaptive immune responses within the local tumors and in distant ones, i.e eliciting Adscopal and/or Abscopal effects.

Physician-Scientist A. Ari Hakimi, MD studies genetic and metabolic mechanisms of immune response in kidney cancers.

Physician-scientist Alan Hanash studies transplant immunology and immune-mediated mechanisms of tissue damage and regeneration.

Optimizing the public health benefit of novel basic science, genomics, and epidemiological findings in cancer through research concerning cancer risk perceptions and health decision-making, especially in skin cancer prevention.

Biomedical engineer Daniel Heller is Head of the Cancer Nanotechnology Laboratory, which invents disruptive technologies to revolutionize the diagnosis and treatment of cancer and allied diseases.

Physician-scientist Daniel Higginson studies a double-strand break repair pathway known as microhomology-mediated end joining, with the overall goal of improving the understanding of radiation treatment and providing insight into therapies for cancers deficient in homologous recombination.

The Hite laboratory studies the mechanisms of metabolite transport and the maintenance of genomic integrity.

Physician-scientist Tobias Hohl studies the molecular pathogenesis of human fungal pathogens and how the immune system responds to them.

The Functional MRI Laboratory provides pre-operative planning for patients with brain tumors and studies the clinical applications of advanced neuroimaging techniques for brain tumor imaging.

Cancer immunologist Alan Houghton studies the immune response to cancer, immune recognition of self and mutated molecules, and development of new immunotherapies.